{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:17:07Z","timestamp":1774005427404,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jclinepi.2026.112138","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T22:49:11Z","timestamp":1768776551000},"page":"112138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Reply to \u201cSome additional considerations on the evidence for fluoxetine in pediatric depression\u201d"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4659-9314","authenticated-orcid":false,"given":"Martin","family":"Pl\u00f6derl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Lyus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Moncrieff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2026.112138_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111396","article-title":"A rebuild the evidence-base\u2013reading of cholinesterase inhibitors\u2019 effect on all-cause mortality in patients with dementia","volume":"172","author":"Blanchard","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2026.112138_bib2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(16)30385-3","article-title":"Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis","volume":"388","author":"Cipriani","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2026.112138_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S2215-0366(20)30137-1","article-title":"Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis","volume":"7","author":"Zhou","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jclinepi.2026.112138_bib4","article-title":"New generation antidepressants for depression in children and adolescents: a network meta-analysis","volume":"2021","author":"Hetrick","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jclinepi.2026.112138_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JRS-210034","article-title":"Restoring the two pivotal fluoxetine trials in children and adolescents with depression","volume":"33","author":"G\u00f8tzsche","year":"2022","journal-title":"JRS"},{"key":"10.1016\/j.jclinepi.2026.112138_bib6","article-title":"Restoring TADS: RIAT reanalysis of the treatment for adolescents with depression study","volume":"36","author":"Aboustate","year":"2025","journal-title":"Int J Risk Saf Med"},{"key":"10.1016\/j.jclinepi.2026.112138_bib7","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1111\/bcp.15345","article-title":"How do they add up? The interaction between the placebo and treatment effect: a systematic review","volume":"88","author":"Boussageon","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jclinepi.2026.112138_bib8","series-title":"Rutter\u2019s child and adolescent psychiatry and psychology","first-page":"898","article-title":"Depressive disorders in children and adolescents","author":"Walkup","year":"2025"},{"key":"10.1016\/j.jclinepi.2026.112138_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjebm-2024-113171","article-title":"Challenges in the selection and measurement of outcomes in psychiatric trials","author":"Juul","year":"2025","journal-title":"BMJ EBM"},{"key":"10.1016\/j.jclinepi.2026.112138_bib10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1503\/cmaj.081514","article-title":"Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies","volume":"180","author":"Barbui","year":"2009","journal-title":"Can Med Assoc J"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435626000090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435626000090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:02:42Z","timestamp":1773964962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435626000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":10,"alternative-id":["S0895435626000090"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112138","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to \u201cSome additional considerations on the evidence for fluoxetine in pediatric depression\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112137","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112138"}}